230 related articles for article (PubMed ID: 28809443)
21. The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration.
Gordon JD; Riggs KW; Rurak DW; Kwan E; Hall C; Abbott FS
Drug Metab Dispos; 1995 Dec; 23(12):1383-9. PubMed ID: 8689948
[TBL] [Abstract][Full Text] [Related]
22. Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation.
Graverini G; Piazzini V; Landucci E; Pantano D; Nardiello P; Casamenti F; Pellegrini-Giampietro DE; Bilia AR; Bergonzi MC
Colloids Surf B Biointerfaces; 2018 Jan; 161():302-313. PubMed ID: 29096375
[TBL] [Abstract][Full Text] [Related]
23. Circadian variation of Valproic acid pharmacokinetics in mice.
Ben-Cherif W; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA
Eur J Pharm Sci; 2013 Jul; 49(4):468-73. PubMed ID: 23707469
[TBL] [Abstract][Full Text] [Related]
24. Challenging the CNS Targeting Potential of Systemically Administered Nanoemulsion Delivery Systems: a Case Study with Rapamycin-Containing Fish Oil Nanoemulsions in Mice.
Kadakia E; Harpude P; Parayath N; Bottino D; Amiji M
Pharm Res; 2019 Jul; 36(9):134. PubMed ID: 31297653
[TBL] [Abstract][Full Text] [Related]
25. Development of β-Carotene-Loaded Organogel-Based Nanoemulsion with Improved In Vitro and In Vivo Bioaccessibility.
Fan Y; Gao L; Yi J; Zhang Y; Yokoyama W
J Agric Food Chem; 2017 Aug; 65(30):6188-6194. PubMed ID: 28696684
[TBL] [Abstract][Full Text] [Related]
26. Placental transfer of valproic acid after liposome encapsulation during in vitro human placenta perfusion.
Barzago MM; Bortolotti A; Stellari FF; Diomede L; Algeri M; Efrati S; Salmona M; Bonati M
J Pharmacol Exp Ther; 1996 Apr; 277(1):79-86. PubMed ID: 8613970
[TBL] [Abstract][Full Text] [Related]
27. Intranasal delivery of topiramate nanoemulsion: Pharmacodynamic, pharmacokinetic and brain uptake studies.
Patel RJ; Parikh RH
Int J Pharm; 2020 Jul; 585():119486. PubMed ID: 32502686
[TBL] [Abstract][Full Text] [Related]
28. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
Ward ES; Pollack GM; Brouwer KL
Drug Metab Dispos; 2000 Dec; 28(12):1433-9. PubMed ID: 11095580
[TBL] [Abstract][Full Text] [Related]
29. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
[TBL] [Abstract][Full Text] [Related]
30. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice.
Darius J; Meyer FP; Sabel BA; Schroeder U
J Pharm Pharmacol; 2000 Sep; 52(9):1043-7. PubMed ID: 11045883
[TBL] [Abstract][Full Text] [Related]
31. Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
Van Matre ET; Cook AM
Neurol Res; 2016 Sep; 38(9):786-91. PubMed ID: 27414414
[TBL] [Abstract][Full Text] [Related]
32. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
33. Nanoemulsions for Intranasal Delivery of Riluzole to Improve Brain Bioavailability: Formulation Development and Pharmacokinetic Studies.
Parikh RH; Patel RJ
Curr Drug Deliv; 2016; 13(7):1130-1143. PubMed ID: 26638977
[TBL] [Abstract][Full Text] [Related]
34. Neuropharmacokinetic evaluation of lactoferrin-treated indinavir-loaded nanoemulsions: remarkable brain delivery enhancement.
Karami Z; Saghatchi Zanjani MR; Rezaee S; Rostamizadeh K; Hamidi M
Drug Dev Ind Pharm; 2019 May; 45(5):736-744. PubMed ID: 30640551
[TBL] [Abstract][Full Text] [Related]
35. Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats.
Zhang X; Liu L; Chai G; Zhang X; Li F
Drug Dev Ind Pharm; 2013 Nov; 39(11):1618-24. PubMed ID: 24087853
[TBL] [Abstract][Full Text] [Related]
36. Time course of alpha-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal gamma-aminobutyric acid levels in comparison to valproic acid.
Tang W; Palaty J; Abbott FS
J Pharmacol Exp Ther; 1997 Sep; 282(3):1163-72. PubMed ID: 9316822
[TBL] [Abstract][Full Text] [Related]
37. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
Rajpoot P; Bali V; Pathak K
Int J Pharm; 2012 Apr; 426(1-2):219-230. PubMed ID: 22301424
[TBL] [Abstract][Full Text] [Related]
38. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
39. Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid.
Shimshoni JA; Yagen B; Pessah N; Wlodarczyk B; Finnell RH; Bialer M
Epilepsia; 2008 Jul; 49(7):1202-12. PubMed ID: 18435754
[TBL] [Abstract][Full Text] [Related]
40. Valproic acid clearance in children with epilepsy.
Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I
J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
